

Notre mission :
Proposer aux entreprises des ressources d'innovation attractives issues de plus de 160 laboratoires et 7200 chercheurs.

The invention concerns new compounds, agonist of peripheral Cannabinoid receptor type 1 (CB1) without effect on central system, for the treatment of metabolic diseases.

Nature de l'offre :

- Improvement in lipid and glucose metabolism,
- Specific to peripheral CB1 receptor,
- No central nervous system effects,
- Low side effects

Domaines d'application :

- Système digestif et métabolisme
- Urologie

Votre contact :

Loic DE MONTESQUIEU
loic.de-montesquieu@ouest-valorisation.fr

DV n°2468 - Treatment of metabolic disease : New agonist of Cannabinoid receptor CB1